Axiom Investors LLC DE Acquires 9,355 Shares of Protagonist Therapeutics, Inc. $PTGX

Axiom Investors LLC DE lifted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 11.7% during the 4th quarter, Holdings Channel reports. The firm owned 89,468 shares of the company’s stock after purchasing an additional 9,355 shares during the quarter. Axiom Investors LLC DE’s holdings in Protagonist Therapeutics were worth $7,814,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Protagonist Therapeutics by 27.2% in the fourth quarter. Vanguard Group Inc. now owns 5,413,690 shares of the company’s stock worth $472,832,000 after acquiring an additional 1,156,461 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Protagonist Therapeutics in the third quarter valued at approximately $72,114,000. Commodore Capital LP bought a new position in shares of Protagonist Therapeutics in the second quarter valued at approximately $59,415,000. UBS Group AG increased its position in shares of Protagonist Therapeutics by 46.1% during the fourth quarter. UBS Group AG now owns 2,770,021 shares of the company’s stock valued at $241,934,000 after acquiring an additional 874,013 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in shares of Protagonist Therapeutics by 83.9% during the third quarter. Wellington Management Group LLP now owns 1,908,446 shares of the company’s stock valued at $126,778,000 after acquiring an additional 870,708 shares during the last quarter. Institutional investors own 98.63% of the company’s stock.

Insider Buying and Selling at Protagonist Therapeutics

In related news, CFO Asif Ali sold 24,765 shares of the business’s stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $104.24, for a total transaction of $2,581,503.60. Following the completion of the transaction, the chief financial officer directly owned 60,753 shares in the company, valued at $6,332,892.72. The trade was a 28.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total value of $7,509,000.00. Following the transaction, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. The trade was a 12.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 263,345 shares of company stock valued at $26,707,266 over the last 90 days. Insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Stock Up 8.0%

Protagonist Therapeutics stock opened at $105.87 on Wednesday. Protagonist Therapeutics, Inc. has a 52 week low of $49.38 and a 52 week high of $107.84. The business has a 50-day simple moving average of $101.38 and a 200 day simple moving average of $92.78. The stock has a market cap of $6.81 billion, a price-to-earnings ratio of -58.49 and a beta of 1.85.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%.The business had revenue of $56.37 million during the quarter, compared to analysts’ expectations of $11.70 million. On average, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Truist Financial raised their target price on Protagonist Therapeutics from $110.00 to $121.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. JPMorgan Chase & Co. lifted their price target on Protagonist Therapeutics from $95.00 to $106.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. Barclays lifted their price target on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $110.00 price target on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Finally, Citigroup reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $115.21.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.